Recent advances in artificial intelligence (AI) have shown great potential in improving cardiovascular pharmacotherapy by optimizing drug selection, predicting therapeutic efficacy and adverse effects, ultimately improving patient outcomes. Leveraging techniques like machine learning and in silico modelling, AI can identify populations likely to benefit from specific treatments, expedite novel drug discovery and reduce costs. Computational methods can also facilitate the detection of drug interactions and tailor interventions based on real-world data, supporting personalized care. Artificial intelligence–based approaches also show promise in streamlining clinical trial design and execution, leveraging on real-time data on patient responsiveness, enhancing recruitment efficiency. 

Read full article (European Heart Journal (2025) 00, 1–12) here!